Venus Remedies Limited
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormo… Read more
Venus Remedies Limited (VENUSREM) - Total Assets
Latest total assets as of September 2025: ₹7.68 Billion INR
Based on the latest financial reports, Venus Remedies Limited (VENUSREM) holds total assets worth ₹7.68 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Venus Remedies Limited - Total Assets Trend (2006–2025)
This chart illustrates how Venus Remedies Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Venus Remedies Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Venus Remedies Limited's total assets of ₹7.68 Billion consist of 63.1% current assets and 36.9% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹575.20 Million | 11.2% |
| Accounts Receivable | ₹1.12 Billion | 15.7% |
| Inventory | ₹1.00 Billion | 14.0% |
| Property, Plant & Equipment | ₹1.51 Billion | 21.1% |
| Intangible Assets | ₹1.05 Billion | 14.6% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Venus Remedies Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Venus Remedies Limited's current assets represent 63.1% of total assets in 2025, an increase from 43.5% in 2006.
- Cash Position: Cash and equivalents constituted 11.2% of total assets in 2025, up from 2.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, a decrease from 18.0% in 2006.
- Asset Diversification: The largest asset category is property, plant & equipment at 21.1% of total assets.
Venus Remedies Limited Competitors by Total Assets
Key competitors of Venus Remedies Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Venus Remedies Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Venus Remedies Limited generates 0.91x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Venus Remedies Limited generates $6.33 in net profit.
Venus Remedies Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.40 | 3.87 | 1.53 |
| Quick Ratio | 2.65 | 2.69 | 0.62 |
| Cash Ratio | 0.15 | 0.31 | 0.00 |
| Working Capital | ₹3.43 Billion | ₹ 2.90 Billion | ₹ 746.30 Million |
Venus Remedies Limited - Advanced Valuation Insights
This section examines the relationship between Venus Remedies Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.66 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 14.2% |
| Total Assets | ₹7.16 Billion |
| Market Capitalization | $65.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Venus Remedies Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Venus Remedies Limited's assets grew by 14.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Venus Remedies Limited (2006–2025)
The table below shows the annual total assets of Venus Remedies Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹7.16 Billion | +14.18% |
| 2024-03-31 | ₹6.27 Billion | +4.28% |
| 2023-03-31 | ₹6.01 Billion | +3.67% |
| 2022-03-31 | ₹5.80 Billion | +4.31% |
| 2021-03-31 | ₹5.56 Billion | -12.84% |
| 2020-03-31 | ₹6.38 Billion | -12.98% |
| 2019-03-31 | ₹7.33 Billion | -2.40% |
| 2018-03-31 | ₹7.51 Billion | -9.44% |
| 2017-03-31 | ₹8.29 Billion | -1.63% |
| 2016-03-31 | ₹8.43 Billion | +0.21% |
| 2015-03-31 | ₹8.41 Billion | +0.80% |
| 2014-03-31 | ₹8.34 Billion | +16.28% |
| 2013-03-31 | ₹7.18 Billion | +25.00% |
| 2012-03-31 | ₹5.74 Billion | +24.56% |
| 2011-03-31 | ₹4.61 Billion | +31.64% |
| 2010-03-31 | ₹3.50 Billion | +18.00% |
| 2009-03-31 | ₹2.97 Billion | +42.58% |
| 2008-03-31 | ₹2.08 Billion | +33.76% |
| 2007-03-31 | ₹1.56 Billion | +149.99% |
| 2006-03-31 | ₹622.28 Million | -- |